How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.
Information source: The Royal Bournemouth Hospital
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Type 2 Diabetes Mellitus
Intervention: Glimepiride (Drug); Sitagliptin (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: The Royal Bournemouth Hospital Official(s) and/or principal investigator(s):
David Kerr, Principal Investigator, Affiliation: Royal Bournemouth Hospital.
Joseph Begley, Principal Investigator, Affiliation: Royal Bournemouth Hospital
Overall contact:
David Kerr, Phone: 01202 704603, Email: david.kerr@rbch.nhs.uk
Summary
The study is aimed at Type 2 Diabetics who are taking Metformin, but whose Diabetes remains
poorly controlled. There are two additional medications already in use, Glimepiride and
Sitagliptin will be compared to assess levels of improvement in Diabetes control.
Clinical Details
Official title: Influence of Improving Glycaemic Control on Glucagon-Like-Peptide-1 Response to an Oral Glucose Load. Comparison of Sulphonylurea With DPP-4 Inhibition.
Study design: Treatment, Randomized, Double Blind (Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Primary outcome: Comparison of GLP-1 response at baseline and after 3 months treatment of both groups.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diabetes Mellitus
- Currently on Metformin but poor glycaemic control,
Exclusion Criteria:
- Under 18 years of age
Locations and Contacts
David Kerr, Phone: 01202 704603, Email: david.kerr@rbch.nhs.uk
Royal Bournemouth Hospital, Bournemouth, Dorset BH7 7DW, United Kingdom; Recruiting
David Kerr, MD, Principal Investigator
Additional Information
Starting date: September 2008
Ending date: September 2010
Last updated: September 25, 2008
|
